Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA ...

The word from the FDA is that Prasad has come back at the request of the regulator's Commissioner, Marty Makary, who ...

Plus more pharma news from the Pharmalittle newsletter.

The shares of biotech companies fell after news that ousted regulator Vinay Prasad is set to go back to the US Food and Drug Administration.

Shares of several biotech firms fell in premarket trading Monday after reports that ousted U.S. Food and Drug Administration vaccine regulator Vinay Prasad will return to the agency.

The public deserves to the full story about Dr. Vinay Prasad's temporary resignation and how this might impact regulatory decisions moving forward.

U.S. President Donald Trump's ally and far-right political activist, Laura Loomer, alleged on Sunday that the rehiring of ...

Dr. Vinay Prasad is back at the FDA less than two weeks after the White House pressed the head of the agency to remove him from his multiple agency leadership roles, an HHS spokesperson said Saturday.

Boehringer Ingelheim's bid to return to the oncology arena has been achieved with an FDA approval for Hernexeos, a new, ...

T O APPRECIATE the dilemmas the Food and Drug Administration (FDA) faces when it reviews new drugs targeting rare diseases, ...

With fall approaching and COVID-19 activity rising across the country, confusion over vaccines is widespread. Mixed messages ...

Buck up, baby boomers. Sixty may not be the new 40, but 80 could soon be the new 60. A trove of new Alzheimer’s research ...